Compounds

Details Compounds Compounds

2008-05-27

2008-05-27

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S517000, C548S518000, C548S523000, C548S526000, C548S557000

Reexamination Certificate

active

07378436

ABSTRACT:
A compound of Formula (I)and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein R1is H, C1-6alkyl, —C(X)Y, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1-8alkyl, C1-8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4alkoxy-C1-6alkyl and C1-4alkyl-S—C1-4alkyl; R2is aryl or heteroaryl, each optionally substituted by at least one substituent independently selected from C1-8alkyl, C1-8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4alkoxy-C1-6alkyl and C1-4alkyl-S—C1-4alkyl; R3is C1-6alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-6alkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1-6alkyl, C1-6alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4alkoxy —C1-6alkyl and C1-4alkyl-S—C1-4alkyl; X is S or O; Y is H, C1-6alkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl; and n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2, m is 0, wherein if m is 0, then * represents a chiral center. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence.

REFERENCES:
patent: 3963745 (1976-06-01), Cale, Jr. et al.
patent: 4020072 (1977-04-01), Hoehn
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5130312 (1992-07-01), Van Daele et al.
patent: 6544922 (2003-04-01), Marks et al.
patent: 2004/0006089 (2004-01-01), Thurieau et al.
patent: 628885 (1978-12-01), None
patent: 138773 (1979-11-01), None
patent: 0379441 (1990-01-01), None
patent: 2295744 (1975-12-01), None
patent: 1574419 (1980-09-01), None
patent: WO 9718813 (1997-05-01), None
patent: WO 9965881 (1999-12-01), None
patent: WO 0144191 (2001-06-01), None
patent: WO 0166114 (2001-09-01), None
patent: WO 0166521 (2001-09-01), None
patent: WO 0224649 (2002-03-01), None
patent: WO 0224694 (2002-03-01), None
patent: WO 03024928 (2003-03-01), None
patent: WO 03037865 (2003-05-01), None
patent: WO 03045949 (2003-06-01), None
patent: WO 2004000808 (2003-12-01), None
patent: WO 2004009549 (2004-01-01), None
patent: WO 2004022536 (2004-03-01), None
patent: WO 2004058705 (2004-07-01), None
Harper et al. “The chemistry and pharmacology of . . . ” CA 62:2980 (1965).
Schaper et al. “Preparation of nicotine acid . . . ” Ca 138:282806 (2003).
Atkinson et al. “Pyrazolecarboximades . . . ” CA 138:368888 (2003).
Zhou et al. “Synthesos of . . . ” CA 139:68991 (1003).
Kadow et al. “Preparation of indole . . . ” CA 139:197364 (2003).
Wilbraham “organic and biological cahemistry” p. 250-251 (1985).
Farina et al. “Quinoline derivatives . . . ” Ca 124:232269 (1996).
Moragues, J. et al., Dopaminergic Activity in a Series of NSubstituted 2-Aminopyrimidines, Farmaco, Ed. Sci., vol. 35, 951-964 (1980).

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2753557